Our Goal is to provide the gold-standard DNA for AAV manufacture

TAAV started as a Joint Venture formed by two leading biotechnology organizations within synthetic DNA and AAV manufacturing.

In 2020 TAAV launched its state-of-the-art facility located in San Sebastian, Spain. The facility is comprised of four suites and additional support labs, that are specifically designed for the manufacture of high quality neDNA™.

TAAV Biomanufacturing Solutions, S.L.U. (TAAV) is a contract development and manufacturing organization (CDMO) owned by Asklepios Biopharmaceutical, Inc. (AskBio) a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG. Our proprietary in vitro DNA amplification technology leads the way in the production of high-quality enzymatic DNA (neDNA™) as an alternative to plasmid DNA that aims to enable better rAAV production.

We view neDNA™ as a disruptive technology in the DNA market creating a new industry standard for transfection-based AAV production. Our synthetic process leads to high yield at small scales, shortening manufacturing timelines, facilitating quicker production of AAV and increasing safety by eliminating residual bacterial sequences of plasmid DNA in the AAV product.

Discover our TAAV-produced dbDNA™ process for rAAV manufacturing .

Send us your CV

Buscamos a personas con pasión por la Biotecnología y la Terapia Génica ¡y esa podrías ser Tú!

Documentos